United Therapeutics (UTHR) stock was on the rise Monday after the biotechnology company announced results from its TETON-1 and TETON-2 studies of Tyvaso. These studies sought to determine the effectiveness of Tyvaso as a treatment for idiopathic pulmonary fibrosis, a chronic, progressive lung disease characterized by the irreversible scarring and stiffening of lung tissue for unknown reasons.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
United Therapeutics noted that positive effects were seen in both the TETON-1 and TETON-2 studies of Tyvaso. The company saw significant treatment effects across all primary endpoints and most secondary endpoints. The TETON-1 study results showed a significant 130.1 mL change in absolute forced vital capacity estimate when compared to placebo.
United Therapeutics also provided investors with its plans for Tyvaso following the positive clinical trials. The company said it intends to submit a New Drug Application (NDA) for Tyvaso to the U.S. Food and Drug Administration. It intends to have this NDA submitted by the end of summer 2026.
United Therapeutics Stock Rallies Today
United Therapeutics stock was up 14.54% on Monday, extending a 24.76% rally year-to-date. The stock has also increased 69.6% over the past 12 months.
UTHR stock trading activity today saw some 250,000 shares change hands, compared to a three-month average daily trading volume of about 528,000 shares.
Is United Therapeutics Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for United Therapeutics is Moderate Buy, based on nine Buy and four Hold ratings over the past three months. With that comes an average UTHR stock price target of $604.33, representing a potential 1.37% upside for the shares.
